Impaired nerve growth factor homeostasis in patients with bipolar disorder

References

• Alleva E, Francia N. 2009. Psychiatric vulnerability: suggestions from animal models and the role of neurotrophins. Neurosci Biobehav Rev 33:525–536.
   PubMed Web of Science ®Google Scholar
• Amorim P. 2000. Mini international neuropsychiatric interview (MINI): validação de entrevista breve para diagnóstico de transtornos mentais. Rev Bras Psiquiatr 22:106–115.
   Google Scholar
• Belmaker RH. 2004. Bipolar disorder. New Engl J Med 351:476–486.
   PubMed Web of Science ®Google Scholar
• Byer LJ. 2008. An evidence-based medicine strategy for achieving remission in bipolar disorder. J Clin Psychiatry 69:31–37.
   PubMedGoogle Scholar
• Bulló M, Peeraully MR, Trayhurn P, Folch J, Salas-Salvadó J. 2007. Circulating nerve growth factor levels in relation to obesity and the metabolic syndrome in women. Eur J Endocrinol 157(3):303–310.
   PubMedGoogle Scholar
• Chao MV. 2003. Neurotrophins and their receptors: a converge point for many signaling pathways. Nat Rev Neurosci 4(4):199–309.
   Google Scholar
• Counts SE, Mufson EJ. 2005. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J Neuropathol Exp Neurol 64(4):263–272.
   PubMedGoogle Scholar
• Cuello AC, Bruno MA, Allard S, Leon W, Iulita MF. 2010. Cholinergic involvement in Alzheimer's disease. A link with NGF maturation and degradation. J Mol Neurosci 40(1–2):230–235.
   PubMedGoogle Scholar
• Goldberg JF, Chengappa KN. 2009. Identifying and treating cognitive impairment in bipolar disorder. Bipolar Disord 11(Suppl 2):123–137.
   PubMed Web of Science ®Google Scholar
• Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. 2009. Inflammation and the phenomenology, pathophysiology, comorbidity, and the treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 70:1078–1090.
   PubMed Web of Science ®Google Scholar
• Hamilton M. 1967. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278–296.
   PubMed Web of Science ®Google Scholar
• Harvey PD. 2009. Pharmacological cognitive enhancement in schizophrenia. Neuropsychol Rev 19(3):324–335.
   PubMedGoogle Scholar
• Hellweg R, von Richthofen S, Anders D, Baethge C, Röpke S, Hartung HD, Gericke CA. 1998. The time course of nerve growth factor content in different neuropsychiatric diseases – a unifying hypothesis. J Neural Transm 105:871–903.
   PubMedGoogle Scholar
• Kale A, Joshi S, Pillai A, Naphade N, Nasrallah H, Mahadik SP. 2009. Reduced cerebrospinal fluid and plasma nerve growth factor in drug-naïve psychotic patients. Schizophr Res 115:209–214.
   PubMed Web of Science ®Google Scholar
• Kapczinski F, Frey BN, Kauer-Sant'Anna M, Grassi-Oliveira R. 2008. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev Neurother 8(7):1101–1113.
   PubMedGoogle Scholar
• Kim HC, Cho YJ, Ahn CW, Park KS, Kim JC, Nam JS, . 2009. Nerve growth factor and expression of its receptors in patients with diabetic neuropathy. Diabet Med 26(12):1228–1234.
   PubMedGoogle Scholar
• McElroy SL, Frye MA, Suppes T, Dhavale D, Keck PE Jr, Leverich GS, . 2002. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 63(3):207–213.
   PubMedGoogle Scholar
• Nico B, Mangieri D, Benagiano V, Crivellato E, Ribatti D. 2008. Nerve growth factor as an angiogenic factor. factor Res 75(2):135–141.
   Google Scholar
• Niewiadomska G, Mietelska-Porowska A, Mazurkiewicz M. 2010. The cholinergic system, nerve growth factor and the cytoskeleton. Behav Brain Res (in press, PMID: 20170684).
   Google Scholar
• Nockher WA, Renz H. 2005. Neurotrophins in clinical diagnostic: pathophysioplogy and laboratory investigation. Clin Chim Acta 352:49–74.
   PubMed Web of Science ®Google Scholar
• Omata N, Murata T, Takamatsu S, Maruoka N, Mitsuya H, Yonekura Y, . 2008. Neuroprotective effect of chronic lithium treatment against hypoxia in specific brain regions with upregulation of cAMP response element binding protein and brain-derived neurotrophic factor but not nerve growth factor: comparasion with acute lithium treatment. Bipolar Disord 10:360–368.
   PubMedGoogle Scholar
• Parikh V, Evans DR, Khan MM, Mahadik SP. 2003. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr Res 60:117–123.
   PubMed Web of Science ®Google Scholar
• Reichardt LF. 2006. Neurotrophin-regulated signaling pathways. Philos Trans R Soc Lond B Biol Sci 361(1473):1545–1564.
   PubMedGoogle Scholar
• Schindowski K, Belarbi K, Buée L. 2008. Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav 7:43–56.
   PubMed Web of Science ®Google Scholar
• Schulte-Herbrüggen O, Braun A, Rochlitzer S, Jockers-Scerübl MC, Hellweg R. 2007. Neurotophic factors – a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases? Curr Med Chem 14(22):2318–2329.
   PubMedGoogle Scholar
• Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, . 1998. The Mini-international neuropsychiatric interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59:4–57.
   Google Scholar
• Teixeira PJ, Rocha FL. 2007. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 29(4):330–336.
   PubMedGoogle Scholar
• Young RC, Biggs JT, Ziegler VE, Meyer DE. 1978. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429–435.
   PubMed Web of Science ®Google Scholar
• Zarate CA, Manji HK. 2008. Bipolar disorder: candidate drugs targets. Mt Sinai J Med 75:226–247.
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Singh J, Manji HK. 2006. Cellular plasticity cascades: targets for the development of novels therapeutics for bipolar disorder. Biol Psychiatry 59:1006–1020.
   PubMed Web of Science ®Google Scholar